Mapping of Charcot-Marie-Tooth Disease Type 1C to Chromosome 16p Identifies a Novel Locus for Demyelinating Neuropathies  by Street, Valerie A. et al.
Am. J. Hum. Genet. 70:244–250, 2002
244
Report
Mapping of Charcot-Marie-Tooth Disease Type 1C to Chromosome 16p
Identifies a Novel Locus for Demyelinating Neuropathies
Valerie A. Street,1 Jeff D. Goldy,2 Alana S. Golden,5 Bruce L Tempel,1 Thomas D. Bird,3,4,6
and Phillip F. Chance2,3
1V. M. Bloedel Hearing Research Center, Department of Otolaryngology–Head and Neck Surgery, 2Departments of Pediatrics, 3Neurology,
and 4Medicine, and 5Undergraduate Neurobiology Research Program, University of Washington, and 6VA Puget Sound Health Care System,
Seattle
Charcot-Marie-Tooth (CMT) neuropathy represents a genetically heterogeneous group of diseases affecting the
peripheral nervous system. We report genetic mapping of the disease to chromosome 16p13.1-p12.3, in two families
with autosomal dominant CMT type 1C (CMT1C). Affected individuals in these families manifest characteristic
CMT symptoms, including high-arched feet, distal muscle weakness and atrophy, depressed deep-tendon reflexes,
sensory impairment, slow nerve conduction velocities, and nerve demyelination. A maximal combined LOD score
of 14.25 was obtained with marker D16S500. The combined haplotype analysis in these two families localizes the
CMT1C gene within a 9-cM interval flanked by markers D16S519 and D16S764. The disease-linked haplotypes
in these two pedigrees are not conserved, suggesting that the gene mutation underlying the disease in each family
arose independently. The epithelial membrane protein 2 gene (EMP2), which maps to chromosome 16p13.2, was
evaluated as a candidate gene for CMT1C.
Charcot-Marie-Tooth disease (CMT; also known as “he-
reditary motor and sensory neuropathy”) is a group of
disorders characterized by degenerative changes in pe-
ripheral motor and sensory nerves. CMT is transmitted
most frequently in an autosomal dominant manner and
affects ∼1 in 2,000 individuals (Skre 1974), making it
one of the most common inherited neurological diseases.
CMT leads to progressive distal muscle weakness af-
fecting the upper and lower limbs, with loss of sensation.
Clinical signs may range from a lack of symptoms to
marked muscle weakness, and, in rare cases, patients
may become wheelchair dependent.
CMT type I (CMT1) is characterized by demyelina-
tion and reduced (!40 m/s) nerve conduction velocities
(NCVs) (Dyck and Lambert 1968). In CMT type II
(CMT2), there is axonal loss, with normal or only mildly
reduced NCVs (Dyck and Lambert 1968). CMT3 (MIM
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145900), also known as “Dejerine-Sottas disease,” may
be inherited as an autosomal recessive or autosomal
dominant trait and is characterized by severe hypomye-
lination, markedly reduced NCVs, and infantile onset
(Lyon 1969; Kennedy et al. 1977). CMT4 is inherited
as an autosomal recessive trait, with patients displaying
early disease onset and rapid distal limb atrophy (Ben
Othmane et al. 1993). In addition to autosomal forms
of CMT, X-linked dominant inheritance also has been
well characterized (Bergoffen et al. 1993).
On the basis of genetic-linkage and gene-sequence
analysis, CMT1 has been divided into four subtypes.
CMT1A (MIM 118220) is associated with a 1.4-Mb
duplication on chromosome 17p11.2-p12 (Lupski et al.
1991; Raeymaekers et al. 1991) with a gene-dosage ef-
fect for peripheral myelin protein (PMP-22 [MIM
601097]) (Matsunami et al. 1992; Patel et al. 1992; Tim-
merman et al. 1992; Valentijn et al. 1992b; Warner et
al. 1996). PMP-22 point mutations have been found in
rare patients with CMT1A who lack the duplication
(Valentijn et al. 1992a; Roa et al. 1993; Nelis et al.
1994). CMT1B (MIM 118200) results from mutations
in the gene on chromosome 1 encoding myelin protein
zero (MPZ [MIM 159440]; also known as “Po pro-
tein”), a major structural protein of peripheral mye-
Figure 1 Haplotype analysis in pedigrees K1550 (A) and K1551 (B). Affected individuals are denoted by blackened symbols, males are
denoted by squares, females are denoted by circles, and deceased persons are indicated by a diagonal line through a symbol. Markers are listed
from telomere (top) to centromere (bottom) and are the same in both pedigrees. The CMT1C-linked haplotype is boxed.
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Table 1
Pedigrees K1550 and K1551: LOD Scores with Chromosome 16p Markers
MARKER (POSITION)
AND PEDIGREEa
LOD SCORE AT RECOMBINATION FRACTION (v) p
Zmax vmax.0 .01 .05 .1 .2 .3 .4
D16S404 (16.7):
K1550  .46 1.56 1.79 1.60 1.11 .53 1.793 .114
K1551  3.07 4.03 4.07 3.44 2.43 1.18 4.105 .076
K1550K1551  3.53 5.59 5.86 5.04 3.54 1.71
D16S519 (19.7):
K1550 3.62 4.83 5.07 4.78 3.83 2.65 1.34 5.083 .038
K1551  3.37 3.70 3.53 2.80 1.86 .80 3.706 .046
K1550K1551  8.20 8.77 8.31 6.63 4.51 2.14
D16S307 (21.8):
K1550 3.27 3.20 2.91 2.54 1.81 1.11 .50 3.270 .000
K1551 4.07 4.00 3.71 3.32 2.47 1.56 .66 4.070 .000
K1550K1551 7.34 7.20 6.62 5.86 4.28 2.67 1.66
D16S310 (23.1):
K1550 5.74 5.64 5.25 4.74 3.67 2.53 1.32 5.740 .000
K1551 5.58 5.48 5.06 4.51 3.35 2.11 .84 5.580 .000
K1550K1551 11.32 11.12 10.31 9.25 7.02 4.64 1.40
D16S500 (27.0):
K1550 6.97 6.86 6.39 5.80 4.53 3.16 1.67 6.970 .000
K1551 7.28 7.15 6.64 5.96 4.53 2.96 1.3 7.280 .000
K1550K1551 14.25 14.01 13.03 11.76 9.06 6.12 2.97
D16S764 (28.7):
K1550  3.59 3.92 3.76 3.08 2.21 1.19 3.923 .047
K1551 2.93 2.89 2.69 2.41 1.79 1.07 .35 2.930 .000
K1550K1551  6.48 6.61 6.17 4.87 3.28 1.54
D16S310 (31.1):
K1550  4.00 4.31 4.10 3.32 2.35 1.25 4.310 .043
K1551  .26 .89 1.16 1.06 .70 .31 1.180 .125
K1550K1551  3.74 5.20 5.26 4.38 3.05 1.56
a Markers are shown in order given by Dib et al. (1996), from telomere to centromere. Marker
map positions (in cM) are based on the Ge´ne´thon and Marshfield human sex-averaged linkage
maps.
lin (reviewed by Lupski [1998]). The CMT1C (MIM
300200) designation was suggested on the basis of ge-
netic evidence, when linkage to regions on chromosomes
17 and 1 were excluded in two CMT1 pedigrees (K1550
and K1551) (Chance et al. 1990, 1992). The CMT1D
gene maps to chromosome 10 and is associated with
mutations in the early growth response 2 gene (EGR2
[MIM 129010]), also known as “Krox-20” (Warner et
al. 1998). In the present article, we describe the mapping
of the CMT1C locus to chromosome 16 and the eval-
uation of the epithelial membrane protein 2 gene (EMP2
[MIM 602334]) as a candidate gene.
Under a protocol of informed consent approved by
the institutional review board of the University of Wash-
ington, Seattle, 15–20 ml of blood were drawn, by ve-
nipuncture, to obtain high-molecular-weight DNA, as
described previously (Neitzel 1986). Pedigrees K1550
and K1551 are of Irish and English descent, respectively,
and are depicted in figures 1A and B, respectively. Male-
to-male transmission is observed in both families, con-
firming autosomal dominant inheritance. Affected in-
dividuals in both pedigrees met widely accepted criteria
for CMT1, including distal muscle weakness and atro-
phy, depressed deep-tendon reflexes, and sensory im-
pairment (Dyck and Lambert 1968). The mean ulnar
(16.7 m/s [ ] and 25.3 m/s [ ], for K1550 andnp 3 np 8
K1551, respectively), median (23 m/s [ ] and 25.8np 5
m/s [ ]), and peroneal (20.4 m/s [ ], 21 m/snp 12 np 4
[ ]) motor-nerve conduction velocities of affectednp 6
K1550 and K1551 individuals are consistent with
CMT1. One affected person (individual 2.7) in pedigree
K1550 was examined further, by sural-nerve biopsy,
which demonstrated “onion bulb hypertrophy” typical
of demyelinating CMT.
A genomewide scan (ABI PRISM Linkage Mapping
Set Version 2; PE Biosystems) was performed in pedi-
grees K1550 and K1551, with informative microsatellite
markers (Dib et al. 1996) spaced at ∼10-cM intervals.
PCR was performed under the conditions recommended
by the manufacturer (PE Biosystems). PCR products
were multiplexed and separated by capillary electropho-
resis using an ABI PRISM 310 Genetic Analyzer (PE
Biosystems). Microsatellite marker-allele data were an-
alyzed by GENESCAN version 3.1.2 and GENOTYPER
Reports 247
Figure 2 CMT1C-containing region of 16p. The CMT1C ge-
netic interval on chromosome 16p13.1-p12.3 is indicated by a bracket
( ] ), with flanking markers shown in boldface. Marker map order and
position are based on the Ge´ne´thon and Marshfield human sex-av-
eraged linkage maps. The approximate location of EMP2, based on
previous radiation hybrid mapping, is indicated by a brace ( } ).
version 2.0 (PE Biosystems). Amplification products gen-
erated with the ABI panel sets were sized according to
CEPH control DNA (1347-02) and were assigned allele
numbers consistent with the Marshfield and CEPH des-
ignations (Center for Medical Genetics, Marshfield Med-
ical Research Foundation Web site; Fondation Jean
Dausset–CEPH Web site). New alleles not reported in
the CEPH database include a 205-bp product (desig-
nated “allele 9” in the present study) for marker
D16S500, a 202-bp product (designated “allele 9”) for
marker D16S3075, and a 159-bp product (designated
“allele 10”) for marker D16S519. Two markers,
D16S764 and D16S519, were obtained from Research
Genetics. Under a model of autosomal dominant inher-
itance, pairwise LOD scores were calculated using the
LINKAGE computer program package version 5.1 (La-
throp et al. 1985). Equal recombination rates in males
and females were assumed, and a CMT1-gene frequency
of 0.0005 (Skre 1974) was used for the calculations.
Equal microsatellite marker-allele frequencies were em-
ployed in the analyses, unless CEPH allele frequencies
were available. Haplotypes were constructed on the ba-
sis of known marker orders (Dib et al. 1996).
A combined maximal LOD score (Zmax) of 14.25 was
obtained with marker D16S500, establishing linkage to
chromosome 16. Significant LOD scores ( ) wereZ 1 3max
obtained with multiple markers from chromosome
16p13.1-p12.3, in both pedigrees (table 1). Haplotype
analysis indicated that three markers—D16S3075,
D16S3102, and D16S500—were nonrecombinant with
the CMT1C phenotype in family K1550 (fig. 1A). In-
dividual 2.4 displayed a crossover between markers
D16S519 and D16S3075, defining D16S519 as a distal
flanking marker. Individual 3.2 displayed a crossover
between markers D16S500 and D16S764, defining
D16S764 as a proximal flanking marker. In pedigree
K1551, haplotype analysis determined that four mark-
ers—D16S3075, D16S3102, D16S500, and D16S764
—were nonrecombinant with the CMT1C phenotype
(fig. 1B). Individual 3.8 demonstrated a crossover be-
tween markers D16S519 and D16S3075, confirming
D16S519 as a distal flanking marker. Individuals 3.2,
3.13, and 4.4 showed crossovers between markers
D16S764 and D16S3103. The combined analysis in
these two families suggests that the CMT1C gene maps
within a 9-cM interval between markers D16S519 and
D16S764 (fig. 2). Although no public human-genome
database contains contiguous sequence that spans mark-
ers D16S519 and D16S764, available sequence infor-
mation indicates the presence of 20 genes in this in-
terval on chromosome 16p.
EMP2 has been mapped to chromosome 16p13.2
(Liehr et al. 1999) and is a member of the PMP-22 gene
family (Taylor and Suter 1996). Given the coincident
map position of EMP2 and CMT1C, the coding exon
and flanking intron nucleotide sequence for EMP2
(GenBank accession numbers NT_019611 and X94770)
were compared between affected and unaffected family
members in pedigrees K1550 and K1551 (table 2), but
no disease-associated mutations were detected. An
EMP2C/T single-nucleotide polymorphism (SNP) is pre-
sent 14 bp 5′ of the AG splice-acceptor site in the third
coding exon. Some affected individuals in both pedigrees
are heterozygous at the C/T SNP, suggesting that the
EMP2 gene is not deleted in individuals with CMT1C.
In an effort to genetically map EMP2 relative to
CMT1C, we directly sequenced this area in key individ-
uals (2.4 and 3.7 from K1500 and 3.7, 3.8, 4.5, and 4.6
from K1551), including those displaying crossover
events between D16S519 and D16S3075. The C/T SNP
was uninformative in family K1551, since affected in-
dividual 3.8 was T/T homozygous. In pedigree K1550,
the genotype of unaffected individual 1.2 was T/T, and
three of her affected offspring (2.2, 2.4, and 2.7) were
C/T heterozygous, suggesting that the C allele was car-
ried on the affected chromosome inherited from the fa-
ther (1.1). Individual 2.4 transmitted the C allele to her
affected daughter (3.7). Inheritance of the C/T SNP in
family K1550 suggests that EMP2 is contained within
the nonrecombinant CMT-linked haplotype and that it
therefore cannot be eliminated as a candidate gene on
the basis of map position alone.
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Table 2
Genomic Intronic Primer Sequences to Amplify EMP2 Coding Exons
CODING
EXON
PCR PRIMER
(5′r3′)
PRODUCT
SIZE
(bp)
ANNEALING
TEMPERATURE
(C)Forward Reverse
1 actgcaggtatgacgacc acctagtctctggtatgc 487 60
2 acctcctgagtcagtctgc ggagtatgcagtgagtgg 367 65
3 tgctcagaccatgtagacg acgtcccactgtggtacagc 488 65
4 tacccagggtgcactgtgg gaatgtggattctgtactgc 291 65
The bifunctional apoptosis regulator gene (BAR) is an-
other potential candidate gene for CMT1C. BAR appears
to encode a scaffold protein that is able to modulate both
(1) the extrinsic apoptotic pathway activated by extra-
cellular ligands binding to membrane-spanning tumor-
necrosis–factor receptors and (2) the intrinsic apopto-
tic pathway triggered by mitochondrial release of cy-
tochrome c (Zhang et al. 2000). Like BAR, the PMP-22
gene underlying CMT1A also regulates programmed cell
death (Brancolini et al. 1999).
CMT demonstrates extensive genetic heterogeneity,
with nine different genes thus far identified that, when
altered, can give rise to a CMT phenotype. These CMT
genes are PMP-22, MPZ, EGR2, the connexin-32 gene
(Cx-32 [MIM 304040]), the neurofilament-light gene
(NF-L [MIM 162280]) (Mersiyanova et al. 2000; De
Jonghe et al. 2001), the myotubularin-related protein 2
gene (MTMR2 [MIM 603557]) (Bolino et al. 2000),
N-myc downstream-regulated gene 1 (NDRG1 [MIM
605262]) (Kalaydjieva et al. 2000), the periaxin gene
(PRX [MIM 605725]) (Boerkoel et al. 2001; Guilbot et
al. 2001), and the b isoform of kinesin superfamily mo-
tor protein B gene (KIF1Bb) (Zhao et al. 2001). The
proteins encoded by these genes are involved in a variety
of cellular functions, including cytoskeletal scaffolding
(in the case of NF-L), the transport of small molecules
within and across the myelin sheath (in the case of Cx-
32), signal transduction (in the case of MTMR2), cell
arrest/proliferation and differentiation (in the case of
PMP-22, NDRG1, and EGR2), myelin maintenance
and formation (in the case of MPZ and PRX) (Gilles-
pie et al. 2000), and axonal transport (in the case of
KIF1Bb).
In the present study, we have firmly established the
category of CMT1C and have identified an additional
locus for CMT, on chromosome 16. Therefore, patients
diagnosed clinically with CMT1 may have alterations in
PMP-22 (in the case of CMT1A), MPZ (in the case of
CMT1B), an unidentified gene on chromosome 16 (in
the case of CMT1C), or EGR2 (in the case of CMT1D).
The CMT1A duplication on chromosome 17p11.2-p12,
which contains PMP-22, accounts for ∼70% of all cases
of CMT1 (Wise et al. 1993). The remaining 30% of
CMT1 cases may be caused by PMP-22, MPZ, EGR2,
or chromosome 16 gene mutations. We cannot predict
the contribution that CMT1C gene mutations will make
to the remaining 30% of CMT1 cases. However, it is
noteworthy that two unrelated families with CMT1C
that have been discussed in the present article were iden-
tified in a limited geographical region of the Pacific
Northwest. The CMT1C-linked haplotypes—4-3-4-2-9-
1-3 in K1550 and 5-4-3-1-1-2-7 in K1551—are not con-
served, suggesting that the gene mutation underlying the
disease in each family arose independently; this raises
the possibility that mutations in the CMT1C gene might
not be rare. Discovery of the CMT1C gene will allow
investigators to determine the contribution of CMT1C
gene mutations to the 30% of CMT1 cases not ac-
counted for by the duplication of PMP-22 and will fur-
ther our understanding of the basic processes controlling
myelination.
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